What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?
Kerstin Brinkmann, Ashley P. Ng, Carolyn A. de Graaf, Andreas Strasser
Topics & Concepts
CarcinogenesisCancerBcl-2 familyCancer researchApoptosisVenetoclaxBiologyCancer cellDrug developmentProgrammed cell deathDrugMedicineImmunologyPharmacologyGeneticsLeukemiaChronic lymphocytic leukemiaCell death mechanisms and regulationPhagocytosis and Immune RegulationRNA Interference and Gene Delivery